Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News. Millions of Medicare recipients could become new weight-loss drug customers with the federal program on the hook for the cost.

Public responses are in for the Consumer Financial Protection Bureau’s (CFPB’s) request for comment as it prepares to revise its open banking rule. The revision comes as a result of the Trump administration's rollback of Biden-era rules, which has once again shaken up a decade-long debate. Banks have good reasons to be upset with the original rule and are using this rulemaking opportunity to relitigate the issues they lost on. Their less fintech-friendly angle risks rupturing industry relationships that were crucial to the private-sector solution. However, it gives them a defensive posture to protect what they see as their business interests under threat.

The price of newly launched prescription drugs increased by more than half over two years, according to new analysis from the Institute for Clinical and Economic Research (ICER). Although the industry continues to bring innovative therapies to market, high launch prices risk alienating consumers and policymakers. Pharma marketers should prepare for intensified pricing scrutiny and create value-driven narratives anchored in outcomes data, financial support programs, and digital support tools that help patients connect price to health benefits.

The rate of prescription drug approvals decreased while drug review delays and rejections increased in Q3, according to an RBC Capital Markets analysis analysis. Rising rejection rates and delays raise the bar for pharma companies. Drugmakers need to ensure complete, high-quality submissions that anticipate scrutiny and minimize risk. AI tools can play a key role by flagging data gaps, predicting reviewer questions, and optimizing application language to current FDA standards and preferences before submission.

Americans’ trust in federal health agencies and political leaders continues to erode, but while many are confused about what to believe, they still want clearer guidance, per the latest Axios/Ipsos American Health Index. Federal agency staffing cuts, shifting vaccine guidance, and the glut of social media health information have fragmented Americans’ health trust. But trust hasn’t completely disappeared; it’s just gone local. Consumers still believe their doctors and families, creating an opening for healthcare and pharma brands to deliver clear, credible information through those trusted messengers.

Erebor has received conditional approval for a national bank charter. It will be a digitally native competitor to lenders that serve the “innovation economy” and some specific industries: Erebor will focus on B2B services for AI, defense, crypto, and manufacturing companies, with offerings for high-net-worth individuals tied to those sectors. The biggest threat to traditional banks is that payments technology quickly advanced beyond what they can support or understand. Real-time payments solve the instant settlement problem that crypto provides for domestic transactions. But the next generation of changes to payments infrastructure is coming—and very few institutions are ready.

The FDA sent another batch of warning letters to direct-to-consumer pharma advertisers, adding healthcare professional marketing to its list of complaints. Marketers should prepare for more intense medical and legal review checks, but also expand beyond brand messaging rather than pullback on the key HCP prescriber audience.

TikTok announced several upgrades to its AI-powered portfolio at Advertising Week New York on Wednesday. Marketers can use the new tools to increase creative control and drive results with key audiences—but keep in mind that the app’s future in its key market could change ad effectiveness, regardless of what tools the platform offers.

The FDA’s recent crackdown on pharma TV advertising could disproportionately affect Black, Hispanic, and Asian consumers, per a recent Video Advertising Bureau (VAB) report. President Trump recently directed federal health agencies to increase pharma TV advertising enforcement and to change rules to make drugmakers disclose every side effect. Pharma marketers would have to change the ads, spend extensive time and money to change them, or pull them off the air. Marketers and agencies need to think about shifting budgets to digital channels, especially social media and influencer marketing, which are also valuable information health sources for Black, Hispanic and Asian consumers.

The Trump administration is rolling out its own direct-to-consumer (D2C) prescription drug website called TrumpRx.com for Americans to purchase some prescriptions at lower negotiated rates. It’s also inked a specific deal with Pfizer to cut many of its drug prices by 40% or more, and in turn, receive a three-year delay on tariffs. Pharma companies are technically meeting Trump demands with D2C announcements, but the initial moves may not be enough to satisfy policymakers or consumers.

President Trump signed an executive order Thursday approving a proposal to keep TikTok operational in the US under new leadership. Even with a deal set to keep TikTok operational, the app’s new conservative ownership will likely shape the user experience and could impede future growth.

The Trump administration overhauled the H-1B visa program by imposing a $100,000 fee on successful applications, a massive cost increase that is expected to create significant hiring hurdles for the finance industry. The banking talent pipeline is heading toward a painful reckoning. The firms that rely on a continuous stream of junior talent to feed their development teams will suffer most—which will push FIs to change how they staff. The inevitable outcome isn't necessarily hiring more high-skilled US workers, but a forced acceleration of the trend toward offshoring critical technology.

Jimmy Kimmel’s return to Jimmy Kimmel Live! drew 6.3 million viewers, the show’s strongest 18–49 demo ratings for a regular episode in more than a decade, despite being blacked out on affiliates covering nearly a quarter of US households. His free speech monologue went viral, surpassing 19.7 million YouTube views to become his most-watched segment ever. The moment underscores both the enduring ability of linear TV to deliver tentpole audiences and the necessity of digital distribution to sustain reach. By amplifying his message, tactics to cancel Kimmel ultimately expanded his audience—proving digital video is now essential to late-night relevance.

The news: “Jimmy Kimmel Live!” returned to ABC Tuesday night after a nearly weeklong suspension by ABC and Disney. Kimmel’s return may appear to turn the page on a brief-but-heated conflict for legacy media, but it’s only the beginning. Nexstar and Sinclair have said they will air other programming over the show, cutting it out of local ad revenues. Our take: The responses to Trump administration pressures reflect a media industry that will act quickly to avoid becoming a political target, but one that is also willing to lower its head for business interests.

A new schizophrenia drug from Bristol Myers Squibb will get the same price tag in the UK when it launches next year, complying with President Trump’s demand to equalize US drug prices with other developed countries. Trump has public sentiment on his side, with most Americans eager for lower drug costs. We think drugmakers’ public pledges for price cuts and fairer global equality for select brand name drugs can appease both the Trump administration and consumers. Even limited price cuts can have outsized significance in the context of regulatory and public scrutiny.

President Donald Trump is continuing his immigration crackdown with a signed proclamation that adds a $100,000 fee to all new applications for H-1B visas, potentially complicating and clamping down on the market for AI-skilled workers in the US. While intended to spur domestic hiring, the reality is that the US lacks sufficient AI training infrastructure to meet current demand. With a pre-existing lack of employer investment in workforce development to grow US employees’ AI skills, the policy risks shrinking the AI talent pool even more and slowing innovation.

President Trump delayed TikTok’s ban until December 16 and claimed Rupert Murdoch, Lachlan Murdoch, Michael Dell, Larry Ellison, and Marc Andreessen are among investors preparing to acquire its US operations. The potential buyer group—stacked with conservative media and tech moguls—raises concerns over political bias on a platform where left-leaning influencers currently dominate. For advertisers, TikTok’s massive 116.6 million US user base remains critical, but ownership politics could shift user trust and open the door for rivals.

A federal health advisory panel has narrowed the recommendation for childhood measles, mumps, rubella, and varicella (MMRV) vaccine, but indefinitely postponed an expected vote on the hepatitis B vaccine for newborns. Public trust in federal health authorities was already shaky, but every new clash between Kennedy’s anti-vaccine advocates and medical experts makes pharma marketers’ and agencies’ jobs harder. Public health guidance can no longer rest solely with federal agencies. Vaccine makers need to support state and local health agencies, amplify community vaccination efforts, and partner with physicians and trusted online health voices to reinforce safety messages for parents.

British pharma company GSK plans to invest $30 billion in US drug manufacturing and R&D, coinciding with President Trump’s UK state visit and a broader pullback on UK investments by other drugmakers. Since taking office, Trump has issued executive orders and warnings aimed at spurring more US manufacturing and lowering drug prices. While his approach is boosting manufacturing, it doesn’t necessarily translate to lower drug prices. For increased US manufacturing to truly benefit consumers, it needs to be coupled with reforms in how drugs are priced, negotiated, and reimbursed. Without cooperation from the full supply chain—from pharma companies to providers, pharmacy benefit managers, insurers, and federal and state governments—manufacturing growth alone won’t guarantee lower prices for patients.

Cracker Barrel and Jaguar faced fierce backlash over recent rebrands, including criticism from Donald Trump, but their responses diverged sharply. Cracker Barrel scrapped its new logo, ended DEI initiatives, and restored traditional elements after customers accused it of abandoning its heritage. Jaguar, however, doubled down, unveiling a bold redesign and luxury EV despite Trump’s attacks, signaling a pivot toward younger, wealthier buyers. The contrast underscores how brand reinventions can either alienate loyalists or attract new audiences, with success hinging on timing, cultural awareness, and a clear long-term strategy.